Medication for the Treatment of Alcohol Use Disorder (2 credit hours)

Program Summary:  This course explores alcohol use disorder and the medications approved for treating alcohol use disorder including Disulfiram, Naltrexone, and Acamprosate.  Medication assisted treatment can be an effective element of treatment for moderate or severe alcohol use disorder and this course explores screening and assessment, developing a treatment plan, medication-assisted treatment, safety, efficacy, and progress.

This course is recommended for social workers, counselors, and therapists and is appropriate for beginning and intermediate levels of practice.

Find the reading at:  https://www.freestatesocialwork.com/articles/MedicationForTreatment-ofAlcoholUseDisorder.pdf

Publisher:  US Department of Health and Human Services, SAMHSA, Center for Substance Abuse Treatment

Course Objectives:  To enhance professional practice, values, skills, and knowledge by identifying key issues related to medication for the treatment of alcohol use disorder.

Learning Objectives:  Compare the FDA approved medications for the treatment of alcohol use disorder.  Describe treatment considerations for adolescents, young adults, pregnant women, and older adults.  Identify areas for monitoring and indicators of progress.

Review our pre-reading study guide.

In order to purchase or take this course, you will need to log in. If you do not have an account, you will need to register for a free account.

After you log in, a link will appear here that will allow you to purchase this course.

1: Current evidence shows that medications are _____________ in the treatment of alcohol use disorder.
 
 
2: The DSM-5 integrated the DSM-IV alcohol-related disorders into a single disorder called
 
 
 
3: Each of the following is a particularly strong candidate for medication-assisted treatment except:
 
 
 
 
4: Which medication when taken in combination with alcohol, causes a significant physical reaction, involving nausea/vomiting, flushing, and heart palpitations?
 
 
 
5: Which of the following medications blocks opiate receptors that are involved in the rewarding effects of drinking and craving for alcohol?
 
 
 
6: Which of the following medications is not assigned a pregnancy category?
 
 
 
7: Study results have shown that, when used in a primary care setting, the following single interview question was 82% sensitive in detecting individuals who had alcohol problems:
 
 
 
 
8: A patient who reports __________ or more heavy drinking days in the past year should receive further assessment.
 
 
 
 
9: Laboratory testing can
 
 
10: Which of the following conditions warrant a goal of complete abstinence from alcohol rather than a reduction in use?
 
 
 
 
11: Withdrawal generally begins within __________ hours after the blood alcohol level drops.
 
 
 
 
12: In assessing the likelihood and potential severity of withdrawal, the most useful clinical factors are the patient's
 
 
 
 
13: What are the various approaches for treating alcohol use disorder?
 
 
 
 
14: None of the available medications for alcohol use disorder is approved by the FDA for use in people younger than
 
 
 
 
15: The FDA has approved __________ oral medications and ____________ injectable medication for the treatment of alcohol dependence or the prevention of relapse of alcohol use.
 
 
 
 
16: Which medication was approved prior to the requirement that drugs be shown to be effective before being marketed was enacted?
 
 
 
 
17: The low rate of retention and adherence encountered with oral naltrexone led to the development of
 
 
 
18: Which medication has no known clinically significant drug interactions?
 
 
 
 
19: If patients are to be treated for both alcohol and opioid substance use disorder, they should be off all opioids, including prescription opioid analgesics, for a minimum of ________________ before starting naltrexone.
 
 
 
 
20: Which medication blocks the effects of opioid analgesics and has special considerations for pain management?
 
 
 
21: Because alcohol use disorder is a chronic medical problem, patients
 
 
 
 

In order to purchase or take this course, you will need to log in. If you do not have an account, you will need to register for a free account.

After you log in, a link will appear here that will allow you to purchase this course.

 

Free State Social Work, LLC, provider #1235, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. Free State Social Work, LLC maintains responsibility for the program. ASWB Approval Period: 9/6/2018 - 9/6/2021. Social Workers should contact their regulatory board to determine course approval. Social Workers participating in this course will receive 2 continuing education clock hours.

Free State Social Work has been approved by NBCC as an Approved Continuing Education Provider, ACEP NO. 6605. Programs that do not qualify for NBCC credit are clearly identified. Free State Social Work is solely responsible for all aspects of the programs.

This course is approved by the Association of Social Work Boards - ASWB NJ CE Course Approval Program Provider #6 Course #2123 from 11/02/2018 to 11/02/2020. Social workers will receive the following type and number of credit(s): Clinical Social Work Practice 2

G.M. Rydberg-Cox, MSW, LSCSW is the Continuing Education Director at Free State Social Work and responsible for the development of this course.  She received her Masters of Social Work in 1996 from the Jane Addams School of Social Work at the University of Illinois-Chicago and she has over 20 years of experience.  She has lived and worked as a social worker in Chicago, Boston, and Kansas City.  She currently practices in the area of hospital/medical social work.  The reading materials for this course were developed by another organization.

Filed under Addiction, Clinical